Mary's Medicinals is participating in the newly established Centers for Medicare & Medicaid Services (CMS) cannabinoid therapy trial program. Launched today under the CMS Innovation Center, the initiative follows the CMS announcement that cannabinoid-based medicines will be available under the Substance Access Beneficiary Engagement Incentive (BEI) program.
Under the new BEI framework, CMS has established eligibility for products containing up to 3 mg of tetrahydrocannabinols per serving. This threshold allows for the inclusion of non-intoxicating, full-spectrum hemp-derived CBD products, a category where Mary's Medicinals has led since 2013.
The program aims to facilitate access to reliable cannabinoid therapies through established healthcare models under the Accountable Care Organizations (ACO) REACH program and the Enhancing Oncology Model (EOM). Beginning in 2027, eligible patients will have access through the Long-term Enhanced ACO Design (LEAD) model.
By providing access to efficacious, standardized products, the program seeks to evaluate the impact of cannabinoids on patient outcomes and their potential as alternatives to traditional pharmaceutical therapies.
"We look forward to working within the CCMI program to provide its participants with access to reliable products that can improve the lives of millions of patients," said Joe Bayern, CEO of Mary's Medicinals and MM Brands. "We are confident that the results of this program will create a formal pathway toward natural alternatives to opioids and synthetic prescription drugs." Bayern added, "Mary's has a long history of providing therapeutic benefits to our consumers. It is encouraging to see CMS acknowledge these benefits and join us in redefining the perception of cannabinoid-based therapies."
For more information:
Mary's Medicinals
https://marysmedicinals.com/
